Dujiangyan Medical Center

Dujiangyan, China

Dujiangyan Medical Center

Dujiangyan, China
SEARCH FILTERS
Time filter
Source Type

Zhou A.,Chongqing Medical University | Chen S.,Chongqing Medical University | Chen S.,Dujiangyan Medical Center | He B.,Chongqing Medical University | And 3 more authors.
Drug Design, Development and Therapy | Year: 2016

Bioactive mediators, cytokines, and chemokines have an important role in regulating and optimizing the synergistic action of materials, cells, and cellular microenvironments for tissue engineering. RADA self-assembling peptide hydrogels have been proved to have an excellent ability to promote cell proliferation, wound healing, tissue repair, and drug delivery. Here, we report that D-RADA16 and L-RADA16-RGD self-assembling peptides can form stable second structure and hydrogel scaffolds, affording the slow release of growth factor (transforming growth factor cytokine-beta 1 [TGF-beta 1]). In vitro tests demonstrated that the plateau release amount can be obtained till 72 hours. Moreover, L-RADA16, D-RADA16, and L-RADA16-RGD self-assembling peptide hydrogels containing TGF-beta 1 were used for 3D cell culture of bone mesenchymal stem cells of rats for 2 weeks. The results revealed that these three RADA16 peptide hydrogels had a significantly favorable influence on proliferation of bone mesenchymal stem cells and hold some promise in slow and sustained release of growth factor. © 2016 Zhou et al.


Li X.,Eye Hospital | Chen S.,Dujiangyan Medical Center | Zhang B.,Eye Hospital | Li M.,Eye Hospital | And 6 more authors.
International Journal of Pharmaceutics | Year: 2012

In this paper, an in situ injectable nano-composite hydrogel composed of curcumin, N,O-carboxymethyl chitosan and oxidized alginate as a novel wound dressing was successfully developed for the dermal wound repair application. Nano-curcumin with improved stability and similar antioxidant efficiency compared with that of unmodified curcumin was developed by using methoxy poly(ethylene glycol)-b-poly(ε-caprolactone) copolymer (MPEG-PCL) as carrier followed by incorporating into the N,O-carboxymethyl chitosan/oxidized alginate hydrogel (CCS-OA hydrogel). In vitro release study revealed that the encapsulated nano-curcumin was slowly released from CCS-OA hydrogel with the diffusion-controllable manner at initial phase followed by the corrosion manner of hydrogel at terminal phase. In vivo wound healing study was performed by injecting hydrogels on rat dorsal wounds. Histological study revealed that application of nano-curcumin/CCS-OA hydrogel could significantly enhance the re-epithelialization of epidermis and collagen deposition in the wound tissue. DNA, protein and hydroxyproline content in wound tissue from each group were measured on 7th day of post wounding and the results also indicated that combined using nano-curcumin and CCS-OA hydrogel could significantly accelerate the process of wound healing. Therefore, all these results suggested that the developed nano-curcumin/CCS-OA hydrogel as a promising wound dressing might have potential application in the wound healing. © 2012 Elsevier B.V. All rights reserved.


Yuan Z.,Chongqing Medical University | He C.,Dujiangyan Medical Center | Yan S.,Dujiangyan Medical Center | Yan S.,University of Sichuan | And 2 more authors.
World Journal of Urology | Year: 2015

Purpose: To assess the effectiveness of acupuncture in treating female adult with overactive bladder. Materials and methods: After we excluded other causes for storage symptoms, a total of 240 consecutive female patients with overactive bladder were enrolled and completed all aspects of this prospective randomized controlled trial, of which 118 cases were randomly assigned to receive a weekly acupuncture treatment (intervention group), while the other 122 cases were given a pharmacological treatment of oral tolterodine tartrate 2 mg twice daily (control group) for 4 weeks. Data on urgency, incontinence, micturition frequency, nocturia episodes and voided volume were collected and statistically analyzed before and after 4 weekly acupuncture treatments or 4 weeks’ pharmacological treatment using a 3-day micturition diary. Results: The two groups of female patients with overactive bladder were given treatment with weekly acupuncture (n = 118), oral tolterodine tartrate (n = 122) for 4 weeks respectively. At weeks 4, subjects in both intervention and control groups had significant decreases in number of urinary urgency episodes, incontinence episodes, daytime frequency, nocturia episodes and increase in volume voided per micturition without a significant difference in the changes of overactive bladder symptoms between the groups. There were no serious adverse events during the study. Conclusions: This randomized controlled trial demonstrates that acupuncture is safe with significant improvements in patient assessment of overactive bladder symptoms and may be considered a clinically alternative treatment for overactive bladder in female adult. © 2014, Springer-Verlag Berlin Heidelberg.


Chu S.-H.,Shanghai JiaoTong University | Zhou Z.-M.,Dujiangyan Medical Center | Karri S.,Harvard University | Li Z.-Q.,Wuhan University | Zhao J.-M.,Shanghai JiaoTong University
Cancer Gene Therapy | Year: 2014

Our previous study showed that solute carrier family 22 (organic cation transporter) member 18 (SLC22A18) downregulation via promoter methylation was associated with the development and progression of glioma, and the elevated expression of SLC22A18 was found to increase the sensitivity of glioma U251 cells to the anticancer drug 1,3-bis(2-chloroethyl)-1-nitrosourea. In this study, we investigated the possible upregulated expression of SLC22A18-induced enhancement of radiosensitivity of human glioma U251 cells in order to provide evidence in support of further clinical investigations. Stably overexpressing SLC22A18 human glioma U251 cells were generated to investigate the effect of SLC22A18 on the sensitivity of cells to irradiation in vitro using clonogenic survival assay. The apoptosis of U251 cells was examined with terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling assay. DNA damage and repair were measured using γH2AX foci. The effect of SLC22A18 on the in vivo tumor radiosensitivity was investigated in the orthotopic mice model. Upregulated expression of SLC22A18 enhanced the radiosensitivity of glioma U251 cells and also enhanced irradiation-induced apoptosis of U251 cells, but irradiation-induced apoptosis did not correlate with radiosensitizing effect of upregulated expression of SLC22A18. The repair of irradiation-induced double-strand-breaks was retarded in stably overexpressing SLC22A18 U251 cells. In the orthotopic mice model, the upregulated expression of SLC22A18 in U251 cells enhanced the effect of irradiation treatment and increased the survival time of mice. These results show that upregulated expression of SLC22A18 radiosensitizes human glioma U251 cells by suppressing DNA repair capacity. © 2014 Nature America, Inc. All rights reserved.


Chu S.-H.,Shanghai JiaoTong University | Zhou Z.-M.,Dujiangyan Medical Center | Feng D.-F.,Shanghai JiaoTong University | Ma Y.-B.,Shanghai JiaoTong University
Molecular Biology Reports | Year: 2014

Special AT-rich sequence-binding protein-1 (SATB1) has been reported to be over-expressed in many human tumors and knockdown of SATB1 can inhibit tumor growth. The present study was designed to determine the role of SATB1 in the growth of human glioma U251 cells using the plasmid-based SATB1 short hairpin RNA (shRNA) delivered by hydroxyapatite nanoparticles in vitro and in vivo. The in vitro growth, invasion and angiogenesis assays of human glioma U251 cells were done. U251 cells tumor blocks were transplanted into the nude mice. CaCl2-modified hydroxyapatite nanoparticles carrying shRNA-SATB1 plasmids were injected into the tumors. The apoptosis of the tumor U251 cells was examined with TUNEL assay and flow cytometer (FCM). The tumor growth and immunohistochemistry were measured. The expression level of SATB1 mRNA was investigated by RT-PCR. The expression levels of SATB1, Cyclin D1, MMP-2, VEGF, Bax and Caspase-9 protein were determined by western blot analysis. The results showed that hydroxyapatite nanoparticles-delivered shRNA-SATB1 could significantly inhibit the growth, invasion and angiogenesis of U251 cells in vitro and the growth of U251 cells in vivo. FCM results showed that Nano HAP-shRNA-SATB1-induced apoptosis (up to 67.8%). SATB1 expression was strongly down-regulated in the tumor U251 cells. Cyclin D1, MMP-2 and VEGF were also down-regulated in the tumor tissues that also displayed significant increased in Bax expression and Caspase-9 activity. These results show that Nano HAP-shRNA-SATB1 can inhibit the growth of human glioma U251 cells in vitro and in vivo, and hydroxyapatite nanoparticles can be used for the in vitro and in vivo delivery of plasmid-based shRNAs into U251 cells. © Springer Science+Business Media 2013.


PubMed | Chengdu Nuoen Biotechnologies Inc., Chengdu University of Traditional Chinese Medicine and Dujiangyan Medical Center
Type: | Journal: Scientific reports | Year: 2015

MicroRNA (miRNA) studies are experiencing a transition from basic research applications to clinical applications. However, the lack of reliable and sensitive miRNA detection methods has become a bottleneck in the process. Here, we report an absolute quantification method based on the competitive PCR amplification of specific miRNAs and synthetic RNA spike-ins in a single reaction. RNA spike-ins are quantified as dynamic RNA copy number standards and are used to measure selected miRNAs free from the effects of intra-assay variables, including those from individual sample sources. Combined with the size differentiation power of capillary electrophoresis, the content of miRNAs was reproducibly measured, with verifiable detection limits of 10-46 copies over 5-log detection ranges. The direct measurements of miRNAs from 168 human serum samples and their considerable value as a diagnostic for bronchopneumonia and bronchiolitis demonstrate the potential of the assay in clinical applications.


Yuan Z.,Chongqing Medical University | Tang Z.,University of Sichuan | He C.,Dujiangyan Medical Center | Tang W.,Chongqing Medical University
Journal of Diabetes | Year: 2015

Herein we review and discuss epidemiological, clinical, and experimental studies on diabetic cystopathy, a common chronic complication of diabetes mellitus with a variety of lower urinary tract symptoms, providing directions for future research. A search of published epidemiological, clinical, or preclinical trial literature was performed using the key words "diabetes", "diabetic cystopathy", "diabetic bladder dysfunction", "diabetic lower urinary tract dysfunction", "diabetic detrusor instability". The classic symptoms of diabetic cystopathy are decreased bladder sensation, increased bladder capacity, and impaired bladder emptying with resultant increased post-void residual volume. However, recent clinical evidence indicates a presence of storage symptoms, such as overactive bladder symptoms. The pathophysiology of diabetic cystopathy is multifactorial, including disturbances of the detrusor, neuron, urothelium, and urethra. Hyperglycemia, oxidative stress, and polyuria play important roles in inducing voiding dysfunction in diabetic individuals. Treatment choice depends on clinical symptoms and urodynamic abnormalities. Urodynamic evaluation is the cornerstone of diagnosis and determines management strategies. Diabetes mellitus could cause a variety of lower urinary tract symptoms, leading to diabetic cystopathy with broadly varied estimates of the prevalence rates. The exact prevalence and pathogenesis of diabetic cystopathy remains to be further investigated and studied in multicenter, large-scaled, or randomized basic and clinical trials, and a validated and standardized workup needs to be made, improving diabetic cystopathy management in clinical practice. Further studies involving only female diabetics are recommended. © 2015 Ruijin Hospital, Shanghai Jiaotong University School of Medicine and Wiley Publishing Asia Pty Ltd.


PubMed | Chongqing Medical University and Dujiangyan Medical Center
Type: Journal Article | Journal: Journal of cancer research and therapeutics | Year: 2016

Although lobectomy has long been considered the standard procedure for Stage I nonsmall cell lung cancer (NSCLC), the selection of sublobectomy for Stage I NSCLC remains controversial. Amidst growing enthusiasm for minimally invasive surgery, the comparison of clinical outcomes after thoracoscopic sublobectomy versus thoracoscopic lobectomy may be of immense value.The present study aimed to compare the overall survival (OS) and disease-free survival (DFS) outcomes of patients who underwent thoracoscopic sublobectomy with those who underwent thoracoscopic lobectomy for Stage I NSCLC.An electronic search was conducted using five online databases from their dates of inception to February 2014. Hazard ratio (HR) was used in this meta-analysis, calculated from the published survival data.Eight studies met the selection criteria, including a total of 1613 patients (463 patients underwent thoracoscopic sublobectomy, and 1150 patients underwent thoracoscopic lobectomy). From the available data, compared with thoracoscopic sublobectomy, there was a significant benefit of thoracoscopic lobectomy on OS (HR: 1.45; 95% confidence interval [CI]: 1.11-1.90; P = 0.007). However, in subgroup analysis of thoracoscopic segmentectomy and thoracoscopic lobectomy, there was no significant difference in OS (HR: 1.03; 95% CI: 0.76-1.39; P = 0.85) or DFS (HR: 1.19; 95% CI: 0.67-2.10; P = 0.56) between the two groups. In addition, compared with thoracoscopic wedge resection, there was a significant benefit of thoracoscopic lobectomy on OS (HR: 4.19; 95% CI: 2.19-8.03, P < 0.0001).For Stage I patients, thoracoscopic segmentectomy leads to survival rates comparable to thoracoscopic lobectomy. However, the overall several of thoracoscopic lobectomy is superior to that of wedge resection.


Liu L.F.,Dujiangyan Medical Center
Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology | Year: 2011

To explore the dynamic expression and significance of Notch1 in the human kidney tubular epithelial cell transdifferentiation (KTECT)induced by TGF-β(1);. Normal human kidney epithelial cell line (HK-2) was cultured and then divided into blank group, and TGF-β(1);(10 ng/mL) induced group. At the 12 h, 24 h, 48 h and 72 h, the morphologic changes of HK-2 cells were observed under an inverted phase contrast microscope. The expression of α-SMA, E-cadherin and Notchl as well as their mRNA were examined by immunohisto-chemistry staining and RT-PCR respictively. Compared with the normal control group, the expression levels ofα-SMA and Notchl markedly increased in TGF-β(1); induced group (P<0.05), but the expression of E-cadherin obviously reduced(P<0.05). The expression of Notch1 protein and its mRNA was positively correlated to the expression ofα-SMA(r(protein);=0.958; r(mRNA);=0.944; P<0.05), and was negatively correlated to the expression of E-cadherin(r(protein);=-0.937; r(mRNA);=-0.921; P<0.05). Notch1 may participate in the KTECT induced by TGF-β(1);.


Yuan Z.,Dujiangyan Medical Center | He C.,Dujiangyan Medical Center
Kaohsiung Journal of Medical Sciences | Year: 2011

An 8-year-old girl presented with recurrent redness, warming, and pain of the lower extremities for more than 4 years, with exacerbation and accompanying swelling for the past 1 year and ulcers for 1 month. The episodes were triggered by exertion and heat. Her family history revealed that her mother had experienced similar symptoms. Physical examination showed proximal white nails and the distal border in normal color. There was some ulceration in the dorsum of the feet with thick, yellowish secretions, covered by some crusted lesions. Laboratory culture result showed that there were many Monilia guilliermondii in the ulcer specimen. Finally, she was diagnosed with juvenile onset of primary erythromelalgia and was given symptomatic treatment for neuropathic pain and pedal ulcers. Copyright © 2011, Elsevier Taiwan LLC. All rights reserved.

Loading Dujiangyan Medical Center collaborators
Loading Dujiangyan Medical Center collaborators